Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

Learn More

VICC toll-free number 1-877-936-8422

Clinical Trial ECOGHEME2408

Title

A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Follwed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma

Principal Investigator(s)

Nishitha Reddy

Details

  • Protocol No. ECOGHEME2408
  • Open Date: 05/10/2011
  • Staging: Phase II
  • Age Group: Adults
  • Scope: National
  • Objective: To compare the complete remission (CR) rate of BR versus BVR as induction therapy. To compare the 1-year post-induction disease-free survival (DFS) rate with rituximab plus lenalidomide to rituximab alone as continuation therapy.
  • Disease Sites: Lymphoma
  • Therapies: Chemotherapy - cytotoxic; Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: Bendamustine; Bortezomib (BTZ); Lenalidomide; Rituxan; Rituximab (Rituxan); VELCADE
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01216683
  • Secondary Protocol No: E2408

Description

Participants in this research study have untreated high risk follicular lymphoma. The purpose of this study is to try and improve the outcomes for patients with untreated high risk follicular lymphoma. Two new treatment approaches will be evaluated for the treatment of follicular lymphoma. These new treatment agents will be added to standard Bendamustine-Rituximab (BR) induction therapy and to standard rituximab continuation therapy. The purpose of making these additions to standard therapy is to see if induction therapy and/or continuation therapy can improve outcome (i.e., longer remission and possibly improved survival). The study wants to make sure that any side effects from these treatments are tolerable.

Eligibility

Ages Eligible for Study:18 Years and older
Genders Eligible for Study:Both
Accepts Healthy Volunteers:No

Criteria

DISEASE CHARACTERISTICS:
• Histologically confirmed (biopsy-proven) diagnosis of follicular B-cell non-Hodgkin lymphoma with no evidence of transformation to large cell histology
• Patients having both diffuse and follicular architectural elements are eligible if the histology is predominantly follicular (i.e., ≥ 50% of the cross-sectional area) and there is no evidence of transformation to a large cell histology
• Diagnostic confirmation (i.e., core needle or excisional lymph node biopsy) required if the interval since tissue diagnosis of low-grade malignant lymphoma is > 24 months
• Bone marrow biopsy alone not acceptable
• Stage II, III, or IV AND grade 1, 2, or 3a disease
• Must meet criteria for High Tumor Burden (higher risk) as defined by either the Groupe D'Etude des Lymphomes Follicularies (GELF) criteria OR the follicular lymphoma international prognostic index (FLIPI) as defined below:
• Patient must meet ≥ 1 of the following GELF criteria:
• Nodal or extranodal mass ≥ 7 cm
• At least 3 nodal masses > 3.0 cm in diameter
• Systemic symptoms due to lymphoma or B symptoms
• Splenomegaly with spleen > 16 cm by CT scan
• Evidence of compression syndrome (e.g., ureteral, orbital, gastrointestinal) or pleural or peritoneal serous effusion due to lymphoma (irrespective of cell content)
• Leukemic presentation (≥ 5.0 x 10^9/L malignant circulating follicular cells)
• Cytopenias (polymorphonuclear leukocytes < 1.0 X 10^9/L, hemoglobin < 10 g/dL, and/or platelets < 100 x 10^9/L)
• Patient must have a FLIPI-1 score of 3, 4, or 5 (1 point per criterion below):
• Age ≥ 60 years
• Stage III-IV disease
• Hemoglobin level < 12 g/dL
• > 4 nodal areas
• Serum LDH level above normal
• At least 1 objective measurable disease parameter
• Baseline measurements and evaluations (PET and CT) obtained within 6 weeks of randomization
• Measurable disease in the liver is required if the liver is the only site of lymphoma
PATIENT CHARACTERISTICS:
• See Disease Characteristics
• ECOG performance status 0-2
• ANC ≥ 1,500/mm³ (includes neutrophils and bands)
• Platelet count ≥ 100,000/mm³
• Creatinine ≤ 2.0 mg/dL
• AST and ALT ≤ 5 x upper limit of normal (ULN)
• Alkaline phosphatase ≤ 5 x ULN
• Total bilirubin ≤ 1.5 x ULN (patients with known Gilbert disease should contact the study PI)
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use 2 effective methods (1 highly effective and 1 additional effective method) of contraception ≥ 28 days before, during, and for ≥ 28 days after completing study treatment
• HIV-positive patients must meet all of the following criteria:
• HIV is sensitive to antiretroviral therapy
• Must be willing to take effective antiretroviral therapy if indicated
• No history of CD4 < 300 cells/mm³ prior to or at the time of lymphoma diagnosis
• No history of AIDS-defining conditions
• If on antiretroviral therapy, must not be taking zidovudine or stavudine
• Must be willing to take prophylaxis for Pneumocystis jiroveci pneumonia (PCP) during therapy and ≥ 2 months following completion of study therapy or until the CD4 cells recover to over 250 cells/mm³
• No recent history of malignancy except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for ≥ 2 years
• No active, uncontrolled infections (afebrile for > 48 hours off antibiotics)
• No ≥ grade 2 neuropathy
• No myocardial infarction within the past 6 months
• No NYHA class III-IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities
• No serious medical or psychiatric illness likely to interfere with participation in this clinical study
• No known hypersensitivity to boron or mannitol
• No chronic carriers of hepatitis B virus (HBV) with positive hepatitis surface antigen (HBsAg +)
• Patients with a prior history of HBV infection, but immune, with only IgG hepatitis core antibody positive (HBcAb+), must receive antiviral prophylaxis (e.g., lamivudine 100 mg po daily) for ≥ 1 week prior to course 1 and throughout induction and continuation therapy and for ≥ 12 months after the last rituximab dose
• Must register into the mandatory RevAssist® program and be willing and able to comply with the requirements of RevAssist® (for patients randomized to arm III)
PRIOR CONCURRENT THERAPY:
• No prior chemotherapy, radiotherapy, or immunotherapy for lymphoma
• Prednisone or other corticosteroids used for non-lymphomatous conditions will not be considered as prior chemotherapy
• A prior/recent short course (< 2 weeks) of steroids for symptom relief of lymphoma-related symptoms is allowed